ClinicalTrials.gg
CompletedNCT01393613BEACONUpdated Nov 26, 2015Results posted

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia

A Phase 3 interventional study of OPC-34712 and OPC-34712 in Acute Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 60 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-11-26.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
674
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
2nd of 28
674 · median 155
Started
2011
with 6 others
Phase 3
16 of 28
none open now
Registered
5th of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 2nd largest by enrollment, is one of 7 that started in 2011, is one of 16 in phase 3, and was the 5th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy, safety, and tolerability of fixed doses of OPC-34712 versus placebo for the treatment of adult subjects with an acute relapse of schizophrenia.

Read the detailed description

Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the world population. Hallucinations and delusions are the most striking characteristic positive symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and lack of emotion, energy, and motivation) may also be present. The first antipsychotics developed for the treatment of schizophrenia were effective against positive symptoms, but showed little efficacy for negative symptoms and were also associated with a high incidence of side effects. Second generation antipsychotics, represent a significant advancement in the treatment of psychotic disorders because they are effective and at the same time exhibit fewer side effects than first generation antipsychotics. Although generally safer than first generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the safety of these drugs vary considerably.

03

Conditions studied

  • Acute Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by criteria
  2. Subjects who have been recently hospitalized or who would benefit from hospitalization for an acute relapse of schizophrenia
  3. Subjects experiencing an acute exacerbation of psychotic symptoms
  4. Other protocol specific inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  1. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug
  2. Subjects with a current Axis I diagnosis of:

    • Schizoaffective disorder
    • MDD
    • Bipolar disorder
    • Delirium, dementia, amnestic or other cognitive disorder
    • Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder
  3. Subjects presenting with a first episode of schizophrenia
  4. Other protocol specific exclusion criteria may apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
674 participants (actual)

Study arms

  • Experimental
    Dose 3 OPC 34712

    Higher dose, tablet, once daily, for six weeks

    Drug: OPC-34712

  • Experimental
    Dose 2 OPC 34712

    Middle dose, tablet, once daily, for six weeks

    Drug: OPC-34712

  • Experimental
    Dose 1 OPC 34712

    Lower dose, tablet, once daily, for six weeks

    Drug: OPC-34712

  • Placebo comparator
    Placebo

    Placebo, once daily, for six weeks

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score.

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

Secondary outcomes

  1. Mean Change From Baseline to Week 6 in Clinical Global Impression-Severity (CGI-S) Score.

    Severity of illness for each participant was rated using the CGI-S, which was the key secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

  2. Mean Change From Baseline to Week 6 in Personal and Social Performance (PSP) Score.

    PSP is a validated clinician-rated scale that measures personal and social functioning in 4 domains: socially useful activities (e.g. work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

    Time frame: Baseline, Week 3 and Week 6

  3. Mean Change From Baseline to Week 6 in PANSS Positive Subscale Score.

    PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome). The analysis of secondary endpoints was conducted if both comparisons of brexpiprazole 4 mg/day vs placebo and brexpiprazole 2 mg/day vs placebo of the primary endpoint were significant. Although only the comparison of brexpiprazole 4 mg/day vs placebo met the gatekeeping threshold in the primary analysis, statistical testing for the other doses was reported for information.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

  4. Mean Change From Baseline to Week 6 in PANSS Negative Subscale Score.

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

  5. Mean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6.

    The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Time frame: Week 6

  6. Percentage of Participants With Response at Week 6.

    The response rate was defined as reduction of ≥30% from Baseline in PANSS Total Score or CGI-I score of 1 or 2.

    Time frame: Week 6

  7. Percentage of Participants With Discontinuation Rate for Lack of Efficacy at Week 6.

    Participants discontinued for lack of efficacy during the trial were reported here.

    Time frame: Week 6

  8. Mean Change From Baseline to Week 6 in PANSS Excited Component (PEC) Score.

    The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

  9. Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms Score.

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score is the sum of the 8 components of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

  10. Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms Score.

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

  11. Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thought Score.

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

  12. Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility and Excitement Score.

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

  13. Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety and Depression Score.

    Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6

07

Results

Posted Nov 26, 2015

Participant flow

This trial was conducted in 674 participants from 68 trial sites in 8 countries.

Participant flow — Overall Study
MilestoneBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Started120186184184
Completed81129130118
Not completed39575466
Withdrew: Adverse event11111322
Withdrew: Participant met withdrawal criteria0021
Withdrew: Physician decision2001
Withdrew: Withdrawal by subject15252321
Withdrew: Protocol deviation2100
Withdrew: Lack of efficacy9201621

Outcome measures

PrimaryMean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score.

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score.
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Week 1-3.32 ± 0.83-4.35 ± 0.68-5.58 ± 0.68-3.48 ± 0.68
Week 2-7.61 ± 1.09-8.70 ± 0.88-8.42 ± 0.88-6.61 ± 0.89
Week 3-11.56 ± 1.30-10.69 ± 1.06-12.63 ± 1.05-8.95 ± 1.06
Week 4-13.97 ± 1.49-13.12 ± 1.21-15.55 ± 1.19-11.10 ± 1.22
Week 5-14.47 ± 1.71-14.11 ± 1.38-17.26 ± 1.37-11.89 ± 1.40
Week 6-16.90 ± 1.86-16.61 ± 1.49-20.00 ± 1.48-13.53 ± 1.52
Statistical analysis
  • Brexpiprazole 2 mg vs Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.0093MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.0022 · Mean difference (final values): -6.47 · 95% CI -10.6 to -2.35MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = 0.1448 · Mean difference (final values): -3.08 · 95% CI -7.23 to 1.07MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.1588 · Mean difference (final values): -3.37 · 95% CI -8.06 to 1.32MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
SecondaryMean Change From Baseline to Week 6 in Clinical Global Impression-Severity (CGI-S) Score.

Severity of illness for each participant was rated using the CGI-S, which was the key secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 6 in Clinical Global Impression-Severity (CGI-S) Score.
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Week 1-0.11 ± 0.05-0.16 ± 0.04-0.22 ± 0.04-0.12 ± 0.04
Week 2-0.31 ± 0.06-0.40 ± 0.05-0.40 ± 0.05-0.36 ± 0.05
Week 3-0.63 ± 0.07-0.60 ± 0.06-0.69 ± 0.06-0.44 ± 0.06
Week 4-0.67 ± 0.09-0.72 ± 0.07-0.85 ± 0.07-0.58 ± 0.07
Week 5-0.81 ± 0.10-0.79 ± 0.08-1.02 ± 0.08-0.68 ± 0.08
Week 6-0.91 ± 0.11-0.99 ± 0.09-1.19 ± 0.08-0.81 ± 0.09
Statistical analysis
  • Brexpiprazole 2 mg vs Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.0069MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.0015 · Mean difference (final values): -0.38 · 95% CI -0.62 to -0.15MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = 0.1269 · Mean difference (final values): -0.19 · 95% CI -0.42 to -0.05MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.4449 · Mean difference (final values): -0.10 · 95% CI -0.37 to 0.16MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
SecondaryMean Change From Baseline to Week 6 in Personal and Social Performance (PSP) Score.

PSP is a validated clinician-rated scale that measures personal and social functioning in 4 domains: socially useful activities (e.g. work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

Time frame:
Baseline, Week 3 and Week 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 6 in Personal and Social Performance (PSP) Score.
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Week 36.97 ± 0.906.85 ± 0.737.12 ± 0.715.80 ± 0.73
Week 611.73 ± 1.1910.52 ± 0.9513.11 ± 0.948.52 ± 0.97
Statistical analysis
  • Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.0005 · Mean difference (final values): 4.59 · 95% CI 2.02 to 7.17MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = 0.1286 · Mean difference (final values): 2.00 · 95% CI -0.58 to 4.59MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.0332 · Mean difference (final values): 3.21 · 95% CI 0.26 to 6.16MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
SecondaryMean Change From Baseline to Week 6 in PANSS Positive Subscale Score.

PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome). The analysis of secondary endpoints was conducted if both comparisons of brexpiprazole 4 mg/day vs placebo and brexpiprazole 2 mg/day vs placebo of the primary endpoint were significant. Although only the comparison of brexpiprazole 4 mg/day vs placebo met the gatekeeping threshold in the primary analysis, statistical testing for the other doses was reported for information.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 6 in PANSS Positive Subscale Score.
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Week 1-0.93 ± 0.28-1.43 ± 0.23-1.80 ± 0.23-1.25 ± 0.23
Week 2-2.54 ± 0.39-2.76 ± 0.32-2.93 ± 0.32-2.56 ± 0.32
Week 3-3.94 ± 0.46-3.56 ± 0.37-4.43 ± 0.37-3.34 ± 0.37
Week 4-4.83 ± 0.52-4.35 ± 0.42-5.16 ± 0.41-3.93 ± 0.42
Week 5-4.80 ± 0.58-4.68 ± 0.47-6.04 ± 0.46-4.33 ± 0.47
Week 6-5.63 ± 0.62-5.42 ± 0.50-6.65 ± 0.50-4.95 ± 0.51
Statistical analysis
  • Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.0166 · Mean difference (final values): -1.70 · 95% CI -3.08 to -0.31MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = 0.5101 · Mean difference (final values): -0.47 · 95% CI -1.86 to 0.93MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.3938 · Mean difference (final values): -0.68 · 95% CI -2.26 to 0.89MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
SecondaryMean Change From Baseline to Week 6 in PANSS Negative Subscale Score.

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 6 in PANSS Negative Subscale Score.
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Week 1-0.31 ± 0.25-0.52 ± 0.20-0.88 ± 0.20-0.40 ± 0.20
Week 2-1.27 ± 0.29-1.31 ± 0.23-1.42 ± 0.23-0.79 ± 0.24
Week 3-2.06 ± 0.35-1.80 ± 0.28-2.15 ± 0.28-1.18 ± 0.28
Week 4-2.56 ± 0.40-2.09 ± 0.32-2.69 ± 0.32-1.67 ± 0.33
Week 5-2.71 ± 0.44-2.50 ± 0.35-2.82 ± 0.35-1.74 ± 0.36
Week 6-2.92 ± 0.48-2.91 ± 0.38-3.36 ± 0.38-2.14 ± 0.39
Statistical analysis
  • Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.0231 · Mean difference (final values): -1.22 · 95% CI -2.28 to -0.17MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = 0.1547 · Mean difference (final values): -0.77 · 95% CI -1.83 to 0.29MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.2004 · Mean difference (final values): -0.78 · 95% CI -1.98 to 0.42MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
SecondaryMean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6.

The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

Time frame:
Week 6
Reported as:
Mean · Units on a scale
Mean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6.
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Mean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6.3.20 ± 1.453.17 ± 1.342.95 ± 1.333.48 ± 1.46
Statistical analysis
  • Brexpiprazole 4 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0009 · Mean difference (final values): -0.49 · 95% CI -0.78 to -0.20Cochran-Mantel-Haenzel (CMH) row mean scores differ test controlling for study center.
  • Brexpiprazole 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0422 · Mean difference (final values): -0.30 · 95% CI -0.60 to -0.01CMH row mean scores differ test controlling for study center.
  • Brexpiprazole 1 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1358 · Mean difference (final values): -0.24 · 95% CI -0.56 to 0.08CMH row mean scores differ test controlling for study center.
SecondaryPercentage of Participants With Response at Week 6.

The response rate was defined as reduction of ≥30% from Baseline in PANSS Total Score or CGI-I score of 1 or 2.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Response at Week 6.
percentage of participantsBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Percentage of Participants With Response at Week 6.43.638.549.731.7
Statistical analysis
  • Brexpiprazole 4 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0006 · Relative risk: 1.54 · 95% CI 1.20 to 2.00CMH general association test
  • Brexpiprazole 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1680 · Relative risk: 1.22 · 95% CI 0.92 to 1.62CMH general association test
  • Brexpiprazole 1 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0433 · Relative risk: 1.35 · 95% CI 1.02 to 1.79CMH general association test
SecondaryPercentage of Participants With Discontinuation Rate for Lack of Efficacy at Week 6.

Participants discontinued for lack of efficacy during the trial were reported here.

Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With Discontinuation Rate for Lack of Efficacy at Week 6.
percentage of participantsBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Percentage of Participants With Discontinuation Rate for Lack of Efficacy at Week 6.7.6911.28.8411.7
Statistical analysis
  • Brexpiprazole 4 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.5202 · Relative risk: 0.82 · 95% CI 0.44 to 1.51CMH general association test
  • Brexpiprazole 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.9894 · Relative risk: 1.00 · 95% CI 0.55 to 1.85CMH general association test
  • Brexpiprazole 1 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4586 · Relative risk: 0.76 · 95% CI 0.36 to 1.59CMH general association test
SecondaryMean Change From Baseline to Week 6 in PANSS Excited Component (PEC) Score.

The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 6 in PANSS Excited Component (PEC) Score.
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Week 1-0.35 ± 0.25-0.46 ± 0.21-1.01 ± 0.21-0.48 ± 0.21
Week 2-0.76 ± 0.32-1.31 ± 0.26-1.21 ± 0.26-0.62 ± 0.26
Week 3-1.21 ± 0.35-1.31 ± 0.28-1.81 ± 0.28-0.82 ± 0.29
Week 4-1.58 ± 0.37-1.52 ± 0.29-2.12 ± 0.29-1.12 ± 0.30
Week 5-1.16 ± 0.42-1.48 ± 0.34-2.27 ± 0.34-0.97 ± 0.35
Week 6-1.94 ± 0.41-1.90 ± 0.33-2.86 ± 0.33-1.47 ± 0.34
Statistical analysis
  • Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.0029 · Mean difference (final values): -1.39 · 95% CI -2.30 to -0.48MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = 0.3559 · Mean difference (final values): -0.43 · 95% CI -1.34 to 0.48MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.3646 · Mean difference (final values): -0.48 · 95% CI -1.51 to 0.56MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
SecondaryMean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms Score.

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score is the sum of the 8 components of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms Score.
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Week 1-1.44 ± 0.29-1.77 ± 0.23-1.75 ± 0.24-1.30 ± 0.24
Week 2-2.97 ± 0.39-3.10 ± 0.32-3.03 ± 0.32-3.03 ± 0.32
Week 3-4.48 ± 0.47-4.09 ± 0.38-4.39 ± 0.37-3.78 ± 0.38
Week 4-5.42 ± 0.53-4.93 ± 0.43-5.48 ± 0.43-4.67 ± 0.44
Week 5-5.86 ± 0.58-5.35 ± 0.47-6.41 ± 0.46-5.47 ± 0.47
Week 6-6.56 ± 0.66-6.26 ± 0.53-7.05 ± 0.53-5.91 ± 0.54
Statistical analysis
  • Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.1273 · Mean difference (final values): -1.14 · 95% CI -2.61 to 0.33MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = 0.6400 · Mean difference (final values): -0.35 · 95% CI -1.83 to 1.12MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.4423 · Mean difference (final values): -0.65 · 95% CI -2.32 to 1.01MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
SecondaryMean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms Score.

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms Score.
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Week 1-0.70 ± 0.28-0.85 ± 0.22-1.12 ± 0.23-0.66 ± 0.22
Week 2-1.71 ± 0.32-1.86 ± 0.26-1.72 ± 0.26-1.38 ± 0.26
Week 3-2.55 ± 0.37-2.30 ± 0.30-2.64 ± 0.30-1.83 ± 0.30
Week 4-3.21 ± 0.43-2.63 ± 0.34-3.17 ± 0.34-2.16 ± 0.35
Week 5-3.35 ± 0.47-3.13 ± 0.38-3.21 ± 0.37-2.24 ± 0.38
Week 6-3.55 ± 0.48-3.53 ± 0.39-3.84 ± 0.39-2.55 ± 0.40
Statistical analysis
  • Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.0194 · Mean difference (final values): -1.28 · 95% CI -2.36 to -0.21MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = 0.0754 · Mean difference (final values): -0.98 · 95% CI -2.06 to 0.10MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.1080 · Mean difference (final values): -1.00 · 95% CI -2.22 to 0.22MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
SecondaryMean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thought Score.

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thought Score.
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Week 1-0.40 ± 0.23-0.46 ± 0.19-0.78 ± 0.19-0.42 ± 0.19
Week 2-1.42 ± 0.27-1.15 ± 0.22-1.37 ± 0.22-0.71 ± 0.23
Week 3-2.35 ± 0.31-1.71 ± 0.25-2.32 ± 0.25-1.35 ± 0.26
Week 4-2.56 ± 0.36-2.27 ± 0.29-2.83 ± 0.29-1.77 ± 0.30
Week 5-2.95 ± 0.41-2.55 ± 0.33-3.42 ± 0.32-2.01 ± 0.33
Week 6-3.46 ± 0.43-2.94 ± 0.35-3.98 ± 0.34-2.59 ± 0.35
Statistical analysis
  • Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.0045 · Mean difference (final values): -1.39 · 95% CI -2.34 to -0.43MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = 0.4753 · Mean difference (final values): -0.35 · 95% CI -1.31 to 0.61MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.1150 · Mean difference (final values): -0.87 · 95% CI -1.96 to 0.21MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
SecondaryMean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility and Excitement Score.

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility and Excitement Score.
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Week 10.03 ± 0.22-0.10 ± 0.18-0.63 ± 0.18-0.21 ± 0.18
Week 2-0.15 ± 0.28-0.65 ± 0.23-0.68 ± 0.23-0.13 ± 0.23
Week 3-0.46 ± 0.30-0.61 ± 0.24-1.16 ± 0.24-0.19 ± 0.24
Week 4-0.74 ± 0.32-0.74 ± 0.26-1.31 ± 0.25-0.39 ± 0.26
Week 5-0.34 ± 0.36-0.60 ± 0.29-1.50 ± 0.29-0.22 ± 0.30
Week 6-0.90 ± 0.36-0.81 ± 0.29-1.89 ± 0.29-0.64 ± 0.30
Statistical analysis
  • Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.0021 · Mean difference (final values): -1.26 · 95% CI -2.05 to -0.46MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = 0.6792 · Mean difference (final values): -0.17 · 95% CI -0.97 to 0.63MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.5752 · Mean difference (final values): -0.26 · 95% CI -1.16 to 0.65MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
SecondaryMean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety and Depression Score.

Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5, and 6
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety and Depression Score.
Units on a scaleBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
Week 1-1.18 ± 0.22-1.10 ± 0.18-1.26 ± 0.18-0.96 ± 0.18
Week 2-1.86 ± 0.27-1.91 ± 0.22-1.60 ± 0.22-1.47 ± 0.22
Week 3-2.43 ± 0.28-2.10 ± 0.23-2.24 ± 0.23-1.97 ± 0.23
Week 4-2.85 ± 0.29-2.70 ± 0.23-2.93 ± 0.23-2.60 ± 0.23
Week 5-2.93 ± 0.31-2.87 ± 0.25-3.09 ± 0.25-2.69 ± 0.26
Week 6-3.57 ± 0.30-3.62 ± 0.24-3.78 ± 0.24-2.93 ± 0.24
Statistical analysis
  • Brexpiprazole 4 mg vs Placebo · Mixed Models Analysis · p = 0.0104 · Mean difference (final values): -0.86 · 95% CI -1.51 to -0.20MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 2 mg vs Placebo · Mixed Models Analysis · p = 0.0373 · Mean difference (final values): -0.70 · 95% CI -1.35 to -0.04MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.
  • Brexpiprazole 1 mg vs Placebo · Mixed Models Analysis · p = 0.0890 · Mean difference (final values): -0.64 · 95% CI -1.39 to 0.10MMRM analysis fixed effect of treatment, trial site, visit, treatment visit interaction, Baseline value, Baseline visit interaction as covariates.

Adverse events

Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 30 (+2) days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole 1 mg—3/120 (2.5%)37/120 (30.8%)
Brexpiprazole 2 mg—4/186 (2.2%)65/186 (34.9%)
Brexpiprazole 4 mg—4/184 (2.2%)66/184 (35.9%)
Placebo—10/184 (5.4%)71/184 (38.6%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
SchizophreniaPsychiatric disorders1/1202/1863/1848/184
Psychotic disorderPsychiatric disorders1/1202/1861/1841/184
AggressionPsychiatric disorders1/1200/1860/1840/184
IrritabilityGeneral disorders0/1200/1860/1841/184
Acute psychosisPsychiatric disorders0/1200/1860/1841/184
Suicidal ideationPsychiatric disorders0/1200/1861/1840/184
Most frequent other events
Most frequent other events
EventBrexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlacebo
InsomniaPsychiatric disorders15/12025/18628/18427/184
HeadacheNervous system disorders9/12020/18619/18427/184
AgitationPsychiatric disorders10/12016/18613/18413/184
AkathisiaNervous system disorders5/1209/18612/18413/184
DyspepsiaGastrointestinal disorders7/1207/1866/1846/184
SchizophreniaPsychiatric disorders4/1206/1867/18410/184

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Brexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlaceboTotal
Mean39.1 ± 11.936.9 ± 10.938.6 ± 11.039.3 ± 10.838.4 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole 1 mgBrexpiprazole 2 mgBrexpiprazole 4 mgPlaceboTotal
Female43647173251
Male77122113111423
08

Study locations

60 sites
  • Little Rock, Arkansas 72201, United States
  • Springdale, Arkansas 72764, United States
  • Escondido, California 92025, United States
  • Long Beach, California 90813, United States
  • Orange, California 92868, United States
  • Pico Rivera, California 90660, United States
  • San Diego, California 92102, United States
  • North Miami, Florida 33161, United States
  • North Miami, Florida 33162, United States
  • Overland Park, Kansas 66212, United States
  • Lake Charles, Louisiana 70629, United States
  • Shreveport, Louisiana 71104, United States
  • Flowood, Mississippi 39232, United States
  • St. Louis, Missouri 63118, United States
  • Buffalo, New York 14215, United States
  • Memphis, Tennessee 38119, United States
  • Austin, Texas 78756, United States
  • Dallas, Texas 75243, United States
  • Houston, Texas 77007, United States
  • Bogota, 00000, Colombia
  • Medellin, 00000, Colombia
  • Pereira, 00000, Colombia
  • Rijeka, 51000, Croatia
  • Zagreb, 10000, Croatia
  • Zagreb, 10090, Croatia
  • Col. Florida, Distrito Federal 01030, Mexico
  • Mexico, Distrito Federal 05300, Mexico
  • Monterrey, Nuevo Leon 64060, Mexico
  • San Luis Potosi, San Luis Potos 78218, Mexico
  • Monterrey, 64060, Mexico
  • Cebu City, 6000, Philippines
  • Davano City, 8000, Philippines
  • Makati City, 1229, Philippines
  • Mandaluyong City, 1553, Philippines
  • Manila, 1000, Philippines
  • Arkhangelsk, 163530, Russian Federation
  • Moscow Region, 142601, Russian Federation
  • Moscow, 117152, Russian Federation
  • Moscow, 119991, Russian Federation
  • Nizhniy Novgorod, 603155, Russian Federation
  • Petrozavodsk, 185000, Russian Federation
  • Samara, 443016, Russian Federation
  • Saratov, 410060, Russian Federation
  • St. Petersburg, 190005, Russian Federation
  • St. Petersburg, 190121, Russian Federation
  • St. Petersburg, 192019, Russian Federation
  • St. Petersburg, 194214, Russian Federation
  • St. Petersburg, 197341, Russian Federation
  • Tomsk, 634014, Russian Federation
  • Village Nikolskoe, 188357, Russian Federation
  • Bojnice, 97201, Slovakia
  • Bratislava, 82606, Slovakia
  • Michalovace, 07101, Slovakia
  • Rimavska Sobota, 97912, Slovakia
  • Roznava, 04801, Slovakia
  • Kaohsiung, 802, Taiwan
  • New Taipei City, 249, Taiwan
  • Taichung, 40447, Taiwan
  • Taipei, 110, Taiwan
  • Taoyuan, 333, Taiwan
09

References and documents

Publications

  • Correll CU, He Y, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. J Clin Psychiatry. 2022 Mar 1;83(2):20m13793. doi: 10.4088/JCP.20m13793. PubMed 35235720 ↗
  • Marder SR, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021 May 1;2(1):sgab014. doi: 10.1093/schizbullopen/sgab014. eCollection 2021 Jan. PubMed 34901863 ↗
  • Newcomer JW, Eriksson H, Zhang P, Weiller E, Weiss C. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. Curr Med Res Opin. 2018 Dec;34(12):2197-2205. doi: 10.1080/03007995.2018.1498779. Epub 2018 Jul 27. PubMed 29985680 ↗
  • Kane JM, Skuban A, Hobart M, Ouyang J, Weiller E, Weiss C, Correll CU. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia. Schizophr Res. 2016 Jul;174(1-3):93-98. doi: 10.1016/j.schres.2016.04.013. Epub 2016 May 14. PubMed 27188270 ↗
  • Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015 May;164(1-3):127-35. doi: 10.1016/j.schres.2015.01.038. Epub 2015 Feb 12. PubMed 25682550 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 1 year 9 months after primary completion. A results delay was requested in Feb 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2011
First posted
Jul 13, 2011
Start
Jul 2011
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results delay requested
Feb 27, 2015
Results first posted
Nov 26, 2015
Last update
Nov 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01393613
Responsible party
Sponsor
First posted
Jul 13, 2011
Start date
Jul 2011
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Nov 26, 2015
Last update
Nov 26, 2015

Study contacts

Aleksandar Skuban, M.D.
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion